Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings

IntroductionAndrogen-receptor pathway inhibitors such as abiraterone and enzalutamide have demonstrated clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to conduct a meta-analysis of published real-world evidence studies comparing o...

Full description

Saved in:
Bibliographic Details
Main Authors: Armen Aprikian, Amit Bahl, Aurelius Omlin, Giulia Baciarello, Abhiroop Chakravarty, Prashanth Kondaparthi, Georgia Gourgioti, Thomas McLean, Alexis Serikoff, Andrew Chilelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Oncology
Subjects:
enzalutamide
abiraterone
prostatic neoplasms
meta-analysis
metastatic castration-resistant prostate cancer
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1491314/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items